---
title: Outcomes and Characteristics of Non-Melanoma Skin Cancers in Patients with
  Myeloproliferative Neoplasms on Ruxolitinib
date: '2023-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37963262/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231115170758&v=2.17.9.post6+86293ac
source: Blood
description: Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave
  aggressively, with adverse features and high recurrence. In our cohort, mortality
  from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment,
  counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are ...
disable_comments: true
---
Non-melanoma skin cancers in ruxolitinib-treated MPN patients behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis . Vigilant skin assessment, counselling on NMSC risks, and prospective ruxolitinib-NMSC studies are ...